AVANIR Pharmaceuticals (NASDAQ:AVNR)

CAPS Rating: 2 out of 5

A pharmaceutical company focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases.

Recs

0
Player Avatar dgoldmeier (20.71) Submitted: 2/9/2011 5:23:42 PM : Outperform Start Price: $4.02 AVNR Score: -29.73

If sales on Nuxedta go well this company can hit a homerun. Well worth the risk.

Featured Broker Partners


Advertisement